Molly Staelens

Wilms tumor, a malignant kidney cancer commonly found in infants and young children, can have a survival rate of over 90% with current treatments. However, around 20% of patients experience relapse after initial treatment, and up to 25% of Wilms tumor survivors may suffer from severe chronic side effects. Furthermore, some subtypes of Wilms tumor have a less favorable prognosis, making it crucial to identify more targeted treatment approaches. However, there are only a limited number of animal models available, hindering our understanding of these tumors. Therefore, the goal of this research project is to develop new models for clinically identified Wilms tumor subtypes using Xenopus tropicalis, an organism in which genetic modification via CRISPR technologies is easily and
efficiently applicable. By thoroughly examining gene expression and the epigenetic state of the genome in these models and comparing them with mouse models and human organoids, we aim to identify new vulnerabilities for subtype specific Wilms tumor. A previously established pipeline for CRISPR mediated dependency mapping is used to assess possible critical genetic vulnerabilities in these tumors. The ultimate aim of this project is to utilize the insights gained to uncover advanced, more precise treatments, thereby enhancing patient care and diminishing the likelihood of enduring complications.
 

• Lab address: Department of Biomedical molecular biology, VIB-UGent, Technologiepark Zwijnaarde 71, 9000 Gent, Belgium
• Vleminckx lab
• Molly Staelens is interested to receive invitations for presentations or talks